Full Name
Prof Sanjiv Chopra
Designation
Professor of Medicine, Harvard Medical School
Co-Director, Division of Continuing Education, Beth Israel Deaconess Medical Center
Editor-in-Chief, Hepatology Section, UpToDate
Co-Director, Division of Continuing Education, Beth Israel Deaconess Medical Center
Editor-in-Chief, Hepatology Section, UpToDate
Bio
Professor of Medicine, Harvard Medical School
Co-Director, Division of Continuing Education, Beth Israel Deaconess Medical Center
Editor-in-Chief, Hepatology Section, UpToDate
Co-Director, Division of Continuing Education, Beth Israel Deaconess Medical Center
Editor-in-Chief, Hepatology Section, UpToDate
Topic
Lifelong Learning: A Look Through The Rear View Mirror and A Peak Ahead | NAFLD: The Burgeoning Epidemic
Abstract
Lifelong Learning: A Look Through The Rear View Mirror and A Peak Ahead
Life-Long Learning is a privilege for all of us in the medical profession. In this talk Dr. Chopra recounts four major stories that played out in the last quarter century - the evolution and understanding of Non-A, Non-B Hepatitis which we currently call Hepatitis C, Celiac Disease, H Pylori, and Non Alcoholic Fatty Liver Disease.
Chronic Hepatitis C was initially treated with Interferon monotherapy for six month and had an abysmal 6% cure rate. Current treatments with oral medications confer a 90-100% cure rate, even in those with cirrhosis of the liver or co-infection with HIV. Celiac Disease is very prevalent and a useful dictum is "Every patient has Celiac Disease unless proven otherwise". The discovery of H Pylori and its eradication in patients with duodenal ulcer disease leads to a cure.
The Nobel Prize in Physiology or Medicine was jointly awarded to Barry Marshall and Robin Warren for their discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease. Michael Houghton, Harvey Alter, and Charles Rice were awarded the Nobel Prize in Physiology or Medicine in 2020 for their discovery of the hepatitis C virus (HCV).
NAFLD: The Burgeoning Epidemic
Non Alcoholic Fatty Liver Disease is the most prevalent chronic liver disease in the world afflicting an estimated 1.5 billion individuals. The majority but not all patients with NAFLD have Metabolic Syndrome. Under the rule break NAFLD are three conditions - Fatty Liver, Non Alcoholic Steatohepatitis, and Cirrhosis. Patients with Cirrhosis are at risk for developing life-threatening liver complications including Primary Hepatocellular Carcinoma (HCC). NASH with Cirrhosis and Liver Failure or HCC is now the number one or two indication for Liver Transplantation in the United States. Individuals with NAFLD who drink coffee have the least amount of hepatic fibrosis. The cornerstone of management includes measures to induce weight loss, vaccination for Hepatitis A & B if needed, drinking 2-4 cups of regular coffee per day and taking 2-4,000 IU of Vitamin D3. Statin use is safe if needed.
Life-Long Learning is a privilege for all of us in the medical profession. In this talk Dr. Chopra recounts four major stories that played out in the last quarter century - the evolution and understanding of Non-A, Non-B Hepatitis which we currently call Hepatitis C, Celiac Disease, H Pylori, and Non Alcoholic Fatty Liver Disease.
Chronic Hepatitis C was initially treated with Interferon monotherapy for six month and had an abysmal 6% cure rate. Current treatments with oral medications confer a 90-100% cure rate, even in those with cirrhosis of the liver or co-infection with HIV. Celiac Disease is very prevalent and a useful dictum is "Every patient has Celiac Disease unless proven otherwise". The discovery of H Pylori and its eradication in patients with duodenal ulcer disease leads to a cure.
The Nobel Prize in Physiology or Medicine was jointly awarded to Barry Marshall and Robin Warren for their discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease. Michael Houghton, Harvey Alter, and Charles Rice were awarded the Nobel Prize in Physiology or Medicine in 2020 for their discovery of the hepatitis C virus (HCV).
NAFLD: The Burgeoning Epidemic
Non Alcoholic Fatty Liver Disease is the most prevalent chronic liver disease in the world afflicting an estimated 1.5 billion individuals. The majority but not all patients with NAFLD have Metabolic Syndrome. Under the rule break NAFLD are three conditions - Fatty Liver, Non Alcoholic Steatohepatitis, and Cirrhosis. Patients with Cirrhosis are at risk for developing life-threatening liver complications including Primary Hepatocellular Carcinoma (HCC). NASH with Cirrhosis and Liver Failure or HCC is now the number one or two indication for Liver Transplantation in the United States. Individuals with NAFLD who drink coffee have the least amount of hepatic fibrosis. The cornerstone of management includes measures to induce weight loss, vaccination for Hepatitis A & B if needed, drinking 2-4 cups of regular coffee per day and taking 2-4,000 IU of Vitamin D3. Statin use is safe if needed.
